- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05948852
Two Hypoabsorption Techniques for the Treatment of Type III Obesity (OASIS) (OASIS)
Randomized Prospective Study Comparing Two Hypoabsorption Techniques for the Treatment of Type III Obesity (Body Mass Index Between 45 - 49.9 Kg/m2): Single Anastomose Duodenal Switch (SADI-S) and Single Anastomose Gastric By-pass (OAGBP)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sergio Sanchez Cordero, MD
- Phone Number: 8902 +34 93 553 12 00
- Email: Sergi.SanchezCordero@sanitatintegral.org
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients over 18 and under 65 who meet criteria for bariatric surgery.
- Maximum BMI between 45 and 50 kg/m2 and indication for surgery in a time
- Signature of the informed consent of the study
- Patients suitable for laparoscopic surgery
Exclusion Criteria:
- Previous bariatric surgery
- 2-stage surgery
- Contraindication for hypoabsorptive surgery due to previous pathology: inflammatory bowel disease, transplant recipient or transplant candidate, previous intestinal resection surgery
- Other associated surgical procedures in the same intervention.
- Conversion to laparotomy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group A: SADI-S
SINGLE ANASTOMOSE DUODENAL SWITCH
|
TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
|
|
Active Comparator: Group B: OAGB
SINGLE ANASTOMOSE GASTRIC BY-PASS
|
TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the percentage of total weight loss (%TWL) of the patients after surgery
Time Frame: Baseline, 1 year, 3 year, 5 year after SADI-S and OAGBP surgery
|
Baseline, 1 year, 3 year, 5 year after SADI-S and OAGBP surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
% of patients with gastroesophageal reflux (acid and bile) after surgery
Time Frame: 1 year, 3 year, 5 year after SADI-S and OAGBP surgery
|
1 year, 3 year, 5 year after SADI-S and OAGBP surgery
|
|
|
Number of deaths in the immediate postoperative period
Time Frame: up to day 90 post-intervention
|
up to day 90 post-intervention
|
|
|
Number of Participants with complications in the immediate postoperative period
Time Frame: up to day 90 post-intervention
|
up to day 90 post-intervention
|
|
|
Ratio of patients with more than 3 loose stools per day
Time Frame: 1 year, 3 years, 5 years after the surgery
|
The ratio of patients with more than 3 loose stools per day will be evaluated as pathological.
To assess the quality of the bowel movements, the Bristol Stool Form Scale questionnaire will be used.
An evaluation of the number of bowel movements and their quality according to the Bristol Stool Form Scale questionnaire will be conducted at 1 year, 3 years, and 5 years after the surgery
|
1 year, 3 years, 5 years after the surgery
|
|
questionnaire of quality of life
Time Frame: 1 year, 3 years, 5 years after SADI-S and OAGBP surgery
|
The quality of life will be assessed based on the results of the Moorehead-Ardelt II test and the Medical Outcomes Study Short Form-36 questionnaire. The Moorehead-Ardelt II questionnaire includes 6 parameters related to self-esteem, physical activity, social contact, job satisfaction, sexual pleasure, and eating habits. The minimum score is -3 and the maximum is +3. A score of 1.1 to 2 is considered a good result, and anything above 2.1 is considered very good. The SF-36 questionnaire includes 8 parameters such as physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health. The minimum score is 0 and the maximum is 100. |
1 year, 3 years, 5 years after SADI-S and OAGBP surgery
|
|
Number of patients with nutritional deficiencies
Time Frame: 1 year, 3 years, 5 years after SADI-S and OAGBP surgery
|
The main nutritional deficiencies to be evaluated after OAGB (One Anastomosis Gastric Bypass) and SADIS (Single Anastomosis Duodeno-Ileal Switch) are iron and/or vitamin B12 deficiency anemia, deficiencies in fat-soluble vitamins, calcium, and trace elements. The incidence of nutritional deficiencies will be assessed through routine blood tests at 1 year, 3 years, and 5 years after the surgery |
1 year, 3 years, 5 years after SADI-S and OAGBP surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23/001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity, Morbid
-
ClinTrio Ltd.UnknownMorbid Obesity Requiring Bariatric SurgeryBelgium, Germany, Portugal, Austria, Netherlands, Poland, Saudi Arabia
-
Sohag UniversityActive, not recruitingMorbid Obesity Requiring Bariatric SurgeryEgypt
-
General Committee of Teaching Hospitals and Institutes...CompletedMorbid Obesity Requiring Bariatric SurgeryEgypt
-
Centre Hospitalier Universitaire de NiceCompletedMorbid Obesity D009765France
-
Shanghai Jiao Tong University School of MedicineUnknown
-
Yongtao SunThe First Hospital affiliated of Shandong First Medical UniversityNot yet recruiting
-
Hospices Civils de LyonCentre de Recherche en Nutrition Humaine Rhone-Alpe; Institut National de Recherche... and other collaboratorsRecruiting
-
Endolumik, IncWest Virginia UniversityNot yet recruitingMorbid ObesityUnited States
-
Laval UniversityInstitut universitaire de cardiologie et de pneumologie de Québec, University...Recruiting
-
Husson UniversityCompletedMorbid Obesity
Clinical Trials on metabolic surgery (SADIS and OAGB)
-
tarek mahdyCompletedDiabetes Mellitus Type 2 in Obese
-
Médipôle Lyon-VilleurbanneRecruitingObesity | Diabetes Mellitus, Type 2France
-
Hospital Universitario Doctor PesetUnknownDiabetes Mellitus | Sleeve Gastrectomy | Metabolic Surgery | BPGYSpain
-
Jinan University GuangzhouChinese Obesity and Metabolic Surgery CollaborativeRecruitingObesity | Weight Loss | Bariatric Surgery | Metabolic SurgeryChina
-
Pennington Biomedical Research CenterRecruiting
-
National University Hospital, SingaporeNational Medical Research Council (NMRC), SingaporeCompletedComplications | Bariatric Surgery | Cost of CareSingapore
-
British Obesity and Metabolic Surgery SocietyCompleted
-
King's College LondonUnknownNon-alcoholic Fatty Liver Disease (NAFLD) | Non-Alcoholic Steato-Hepatitis (NASH)United Kingdom
-
Royal College of Surgeons in Ireland - Medical...King Faisal Specialist Hospital & Research Center; King Fahad Medical City; King...Active, not recruitingObesity | Non-alcoholic Fatty Liver Disease (NAFLD) | T2DM (Type 2 Diabetes Mellitus) | MASLDBahrain
-
Korea University Anam HospitalMyungmoon Pharma. Co. Ltd.UnknownObesity | Diabetes Mellitus, Type 2 | PreDiabetesKorea, Republic of